New protein kinase CK2 inhibitors: jumping out of the catalytic box.

Abstract : Protein kinases are central components of signal transduction cascades often dysregulated in cancer, and they represent some of the most promising drug targets. However, the target selectivity is a major concern because most described kinase inhibitors target the highly conserved ATP-binding pocket. Recently, new classes of inhibitors that do not compete with ATP and exhibit different mechanisms of action have been described. Overexpression of protein kinase CK2 is an unfavorable prognostic marker in several cancers. Consequently, CK2 has emerged as a relevant therapeutic target. Several classes of ATP-competitive inhibitors have been identified, showing variable effectiveness. The molecular architecture of this multisubunit enzyme could offer alternative strategies to inhibit CK2 functions, and this review illustrates these emerging possibilities.
Type de document :
Article dans une revue
Chem Biol, 2009, 16 (2), pp.112-20. 〈10.1016/j.chembiol.2009.01.004〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00413266
Contributeur : Claude Cochet <>
Soumis le : jeudi 3 septembre 2009 - 16:05:27
Dernière modification le : jeudi 3 septembre 2009 - 16:27:29

Lien texte intégral

Identifiants

Collections

CEA | UGA

Citation

Renaud Prudent, Claude Cochet. New protein kinase CK2 inhibitors: jumping out of the catalytic box.. Chem Biol, 2009, 16 (2), pp.112-20. 〈10.1016/j.chembiol.2009.01.004〉. 〈inserm-00413266〉

Partager

Métriques

Consultations de la notice

85